PR

Perrigo Company plc

PRGOHealthcareNASDAQ

Drug Manufacturers - Specialty & Generic

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$4.25B
-2.8% YoY
Net Income
-$1.43B
-729.7% YoY
EBITDA
-$797.9M
-284.3% YoY
Free Cash Flow
$437.2M

Scan Results

Daily timeframe
2 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Oct 15▲ MACD Positive CrossoverHistogram +0.0888, positive momentum
Oct 14▲ MACD Positive CrossoverHistogram +0.0431, positive momentum
About Perrigo Company plc

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The $2.21B market capitalization puts PRGO squarely in mid-cap range for its industry. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.

Where PRGO stands vs its 150-day and 200-day moving averages

As of the October 15, 2026 close, PRGO finished 38.10% above its 150-day moving average ($11.55) and 33.81% above its 200-day moving average ($11.92). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is PRGO overbought or oversold?

At the October 15, 2026 close, PRGO's RSI(14) was 62.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$2.21B
Fwd P/E6.68
EPS$-12.28
Beta0.69
52W Change-27.3%
Dividend Yield7.27%
ROE-48.8%
Analysis

The company holds $399.7M in cash, though total debt stands at $3.48B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $437.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -48.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.0% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $4.45B (2022) to $4.25B (2025).

With a beta below 0.7, Perrigo Company plc typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Perrigo Company plc carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Perrigo Company plc's trajectory.

Links
More Healthcare stocks
Browse all stocks →
⚠Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms